Using Etomoxir to Inhibit Fatty Acid Oxidation
Mechanism and Range
Etomoxir is converted intracellularly to etomoxiryl-CoA, which inhibits CPT1A at the catalytic site. The inhibition is irreversible in practice, so pre-incubation matters, and the effect persists after washout to the extent that new enzyme is needed.
| Concentration | Selectivity | Observation |
|---|---|---|
| 1–3 µM | Largely CPT1A | Modest FAO inhibition in many cells; requires sensitive flux measurement |
| 5–20 µM | Partial off-target | Adenine nucleotide translocator and complex I effects reported |
| 50–200 µM | Broad | CoA homeostasis disrupted; proliferation inhibited independently of FAO |
| Above 200 µM | Cytotoxic | Not interpretable as CPT1A inhibition |
Caveat on the literature values. The most-cited concentrations in cancer metabolism papers are 100–200 µM, which is in the broad-effect range. A phenotype at that concentration is a phenotype of etomoxir, not necessarily of CPT1A. This is not a minor technicality: it has produced a decade of conflicting conclusions about whether fatty acid oxidation is required for proliferation.
Part 1 — What the Off-Target Effects Are
| Target | Effect | Consequence |
|---|---|---|
| Adenine nucleotide translocator | Reduced ADP/ATP exchange | Respiration falls without a change in substrate supply |
| Complex I | Inhibition at higher concentrations | Oxygen consumption falls for a non-FAO reason |
| Coenzyme A pool | Depletion of free CoA | Broad metabolic disruption, including glucose oxidation |
| Carnitine shuttle | Indirect | Overlaps with the intended effect |
Important distinction. All four of these reduce oxygen consumption, which is why an OCR-based readout cannot distinguish CPT1A inhibition from the off-target effects. The discriminating measurement is substrate-specific: palmitoyl-carnitine-driven respiration in permeabilised cells, where the substrate bypasses CPT1A and the off-target effects are visible as a change in the palmitoyl-carnitine-independent baseline.
Part 2 — Design
| Parameter | Recommendation | Why |
|---|---|---|
| Pre-incubation | 30–60 minutes before the fatty acid challenge | Irreversible inhibition requires time to accumulate |
| Concentration series | 1, 3, 10, 30 µM | Establishes where the effect saturates and where off-target appears |
| Vehicle | DMSO or ethanol matched | Both solvents affect respiration at higher volumes |
| Positive control | A genetic CPT1A knockdown, or octanoate | Route specificity |
| Readout | Acyl-carnitine profile plus a flux measurement | Together they distinguish entry from downstream effects |
| Viability | At the assay timepoint | Separates metabolic from cytotoxic effects |
The fourth row is the one that converts the experiment from suggestive to interpretable. Octanoate enters mitochondria without CPT1A, so if etomoxir blocks palmitate oxidation but not octanoate oxidation, the effect is at the entry step. That comparison is cheap and decisive.
Part 3 — Alternative and Complementary Tools
| Tool | Mechanism | Best use |
|---|---|---|
| CPT1A knockdown or knockout | Genetic | Specificity; slower |
| Inducible CPT1A knockdown | Genetic, titratable | Avoids clonal adaptation |
| Ranolazine | Partial CPT1 inhibition | Clinical context; partial effect |
| Perhexiline | CPT1 and CPT2 inhibition | Cardiac models; narrow therapeutic window |
| Malonyl-CoA elevation (ACC activation) | Physiological inhibition | Tests the endogenous gate |
| Substrate restriction (low fatty acid medium) | Removes substrate | Tests dependence without inhibiting the enzyme |
Readout note. Substrate restriction is the cleanest way to test whether a phenotype depends on fatty acid oxidation, because it removes the substrate rather than inhibiting a protein. In medium with delipidated serum and no added fatty acids, oxidation is low; the phenotype that disappears under those conditions is FAO-dependent by definition. The limitation is that serum delipidation removes other lipids as well, so the comparison should include a lipid add-back arm.
Part 4 — Interpreting Partial Effects
Etomoxir rarely abolishes fatty acid oxidation completely. A partial reduction is the expected result at selective concentrations and should be reported as such.
- • A 30–50% reduction at 1–3 µM is consistent with partial CPT1A inhibition and is adequate to test dependence if the phenotype follows the flux.
- • A near-complete reduction at high concentration is more likely to reflect off-target effects than complete enzyme inhibition.
- • A phenotype without a flux change indicates that the effect is not mediated by oxidation, whatever the concentration.
The third pattern is common and is usually reported as "FAO inhibition prevented the phenotype", which inverts the logic: if flux did not change, the phenotype cannot be attributed to flux.
Part 5 — Common Failures
- • 100–200 µM used as "CPT1A inhibition".
- • No pre-incubation, so the irreversible inhibition has not developed.
- • OCR used as the only readout, which cannot separate the targets.
- • No genetic or substrate-bypass control.
- • Acyl-carnitine profile not measured, discarding the diagnostic of where the block is.
- • Partial inhibition reported as complete.
- • A phenotype without a flux change attributed to FAO.
- • Vehicle effects unmeasured at the volumes used for high concentrations.
Part 6 — Where This Article Connects
This is the protocol companion to the fatty acid oxidation article, which covers the flux measurements and the conditional direction of the effect. The palmitate delivery article determines the substrate load that etomoxir is acting against; the triglyceride assay measures where the unoxidised acyl-CoA went.
If you need FAO dependence tested with a concentration series and a substrate-bypass control, we can scope the design with you.
Contact EDITGENE to request a project consultation or quote.
Scientific scope and validation note
Selectivity, potency and off-target profile vary by cell type, concentration and exposure time; the ranges here are indicative and require local verification.
Inhibition of fatty acid oxidation does not establish that oxidation is required for a phenotype, unless flux and dependence are measured separately.
Scientific interpretation and experimental design
- • Selective only at low micromolar. Above that, it is a different experiment.
- • Pre-incubate. Irreversible inhibition takes time.
- • Octanoate is the bypass control.
- • Acylcarnitines locate the block.
- • Partial inhibition is the expected result. Report it as such.
- • Flux first, phenotype second. Otherwise the attribution fails.
Selected references for further reading
- • Yao CH, et al. Identifying off-target effects of etomoxir reveals that carnitine palmitoyltransferase I is essential for cancer cell proliferation independent of β-oxidation. PLOS Biology. 2018;16:e2003782.
- • Ceccarelli SM, et al. Carnitine palmitoyltransferase (CPT) modulators: a medicinal chemistry perspective. Journal of Medicinal Chemistry. 2011;54:3109–3152.
- • McGarry JD, Brown NF. The mitochondrial carnitine palmitoyltransferase system. European Journal of Biochemistry. 1997;244:1–14.
Related Services
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| PBRM1 Knockout A-549 Cell Line | EDJ0001-K01 | Human | 55193 | Details Get a Quote |
| YTHDC1 Knockout A-549 Cell Line | EDC07652 | Human | 91746 | Details Get a Quote |
| TP53 Knockout HCT 116 Cell Line | EDC07854 | Human | 7157 | Details Get a Quote |
| Sirt2 Knockout MH-S Cell Line | EDJ-KQ78173 | Mouse | 64383 | Details Get a Quote |
| TFE3 Knockout KGN Cell Line | EDJ-KQ48 | Human | 7030 | Details Get a Quote |
| Stub1 Knockout MB49 Cell Line | EDJ-KQ53 | Mouse | 56424 | Details Get a Quote |
| ARID1A Knockout SNK-6 Cell Line | EDJ-KQ64 | Human | 8289 | Details Get a Quote |
| Tet1 Knockout Kupffer Cell Line | EDJ-KQ88 | Mouse | 52463 | Details Get a Quote |
| NR1H3 Knockout HEK293T Cell Line | EDJ-KQ109 | Human | 10062 | Details Get a Quote |
| NR1H2 Knockout HEK293T Cell Line | EDJ-KQ110 | Human | 7376 | Details Get a Quote |
| RPS6KB2 Knockout HEK293 Cell Line | EDJ-KQ125 | Human | 6199 | Details Get a Quote |
| SMAD6 Knockout HEK293 Cell Line | EDJ-KQ126 | Human | 4091 | Details Get a Quote |
| JUN Knockout HEK293 Cell Line | EDJ-KQ176 | Human | 3725 | Details Get a Quote |
| JUN Knockout HEK293T Cell Line | EDJ-KQ184 | Human | 3725 | Details Get a Quote |
| ALKBH5 Knockout HEK293 Cell Line | EDJ-KQ186 | Human | 54890 | Details Get a Quote |
- 1
- 2
- ...
- Next Page »